240 related articles for article (PubMed ID: 32028750)
21. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab-ipilimumab in renal cell carcinoma metastatic to the bones: A case report.
Di Napoli M; Pisano C; Setola SV; Perdonà S; Feroce F; Pignata S
Acta Biomed; 2022 Jun; 93(S1):e2022132. PubMed ID: 35765962
[TBL] [Abstract][Full Text] [Related]
23. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
24. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
25. Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.
Kobari Y; Yoshida K; Iizuka J; Kondo T; Ishida H; Tanabe K; Takagi T
In Vivo; 2021; 35(6):3585-3589. PubMed ID: 34697199
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
[TBL] [Abstract][Full Text] [Related]
28. [A Case of Metastatic Renal Cell Carcinoma with Arthritis and Colitis Due to Immune-Related Adverse Events During Ipilimumab-Nivolumab Combination Therapy].
Toyoshima M; Ikarashi D; Tsuboi H; Moriwaka M; Tamada S; Matsuura T; Maekawa S; Kato R; Kanehira M; Takata R; Sugimura J; Obara W
Hinyokika Kiyo; 2023 Aug; 69(8):227-232. PubMed ID: 37667600
[TBL] [Abstract][Full Text] [Related]
29. [A Case of Metachronous Occurrence of Interstitial Pneumonitis and Hypophysitis Following Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma].
Hayase T; Washino S; Mayumi S; Yazaki K; Nakamura Y; Oshima M; Konishi T; Saito K; Miyagawa T
Hinyokika Kiyo; 2021 Jun; 67(6):239-243. PubMed ID: 34265899
[TBL] [Abstract][Full Text] [Related]
30. Successful Pregnancy and Cancer Outcomes With Ipilimumab and Nivolumab for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
Zambrana F; Barbancho C; Huelves M; García de Santiago B; Martín Y; Muñoz de Lengaria M; de Velasco G
J Immunother; 2023 Jan; 46(1):27-28. PubMed ID: 36327112
[TBL] [Abstract][Full Text] [Related]
31. Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab.
Remolina-Bonilla YA; Jimenez-Franco B; Lam ET; Bourlon MT
Oncology (Williston Park); 2020 May; 34(5):171-174. PubMed ID: 32644176
[TBL] [Abstract][Full Text] [Related]
32. NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma.
Adler AI; Brooke A; Elsada A; Landells L
Lancet Oncol; 2019 Jul; 20(7):904-905. PubMed ID: 31103427
[No Abstract] [Full Text] [Related]
33. Nivolumab plus ipilimumab in advanced renal-cell carcinoma.
Gunjur A
Lancet Oncol; 2018 May; 19(5):e232. PubMed ID: 29606588
[No Abstract] [Full Text] [Related]
34. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma.
Teló GH; Carvalhal GF; Cauduro CGS; Webber VS; Barrios CH; Fay AP
Ann Oncol; 2017 Jan; 28(1):191-192. PubMed ID: 28043983
[No Abstract] [Full Text] [Related]
35. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
36. [INTERSTITIAL NEPHRITIS CAUSED BY IPILIMUMAB AND NIVOLUMAB COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA: A CASE REPORT].
Ishii M; Takezawa K; Imamura R; Fukuhara S; Fujita K; Uemura M; Kiuchi H; Nonomura N
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):109-112. PubMed ID: 35444079
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.
Hino C; Nishino K; Pham B; Jeon WJ; Nguyen M; Cao H
Front Immunol; 2022; 13():993622. PubMed ID: 36052087
[TBL] [Abstract][Full Text] [Related]
38. Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care.
Nizam A; Aragon-Ching JB
Cancer Biol Ther; 2019; 20(1):6-7. PubMed ID: 30332546
[TBL] [Abstract][Full Text] [Related]
39. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
[TBL] [Abstract][Full Text] [Related]
40. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]